...
search icon
pulm-img

Pulmatrix Inc, Common Stock

PULM

NAQ

$6.01

+$0.02

(0.33%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$21.95M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
51.28K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.99
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.55 L
$8.44 H
$6.01

About Pulmatrix Inc, Common Stock

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FramePULMSectorS&P500
1-Week Return-16.53%0.49%-0.42%
1-Month Return0.84%-3.1%-2.2%
3-Month Return179.53%-8.59%2.38%
6-Month Return190.34%-4.57%5.1%
1-Year Return194.61%-0.94%23.79%
3-Year Return-23.24%2.88%26.66%
5-Year Return-80.61%35.84%81.16%
10-Year Return-99.67%98.8%191.72%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue7.91M12.63M5.17M6.07M7.30M[{"date":"2019-12-31","value":62.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":40.91,"profit":true},{"date":"2022-12-31","value":48.05,"profit":true},{"date":"2023-12-31","value":57.76,"profit":true}]
Cost of Revenue12.85M-15.38M1.54M15.52M[{"date":"2019-12-31","value":82.77,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":99.12,"profit":true},{"date":"2022-12-31","value":9.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(4.93M)12.63M(10.21M)6.07M(8.22M)[{"date":"2019-12-31","value":-39.06,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-80.84,"profit":false},{"date":"2022-12-31","value":48.05,"profit":true},{"date":"2023-12-31","value":-65.06,"profit":false}]
Gross Margin(62.39%)100.00%(197.58%)100.00%(112.63%)[{"date":"2019-12-31","value":-62.39,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-197.58,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-112.63,"profit":false}]
Operating Expenses21.33M22.50M21.76M25.02M22.04M[{"date":"2019-12-31","value":85.27,"profit":true},{"date":"2020-12-31","value":89.92,"profit":true},{"date":"2021-12-31","value":86.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":88.09,"profit":true}]
Operating Income(20.69M)(573.00K)(20.17M)(18.95M)(14.74M)[{"date":"2019-12-31","value":-2069200000,"profit":false},{"date":"2020-12-31","value":-57300000,"profit":false},{"date":"2021-12-31","value":-2016700000,"profit":false},{"date":"2022-12-31","value":-1894700000,"profit":false},{"date":"2023-12-31","value":-1474000000,"profit":false}]
Total Non-Operating Income/Expense397.00K(9.36M)3.00K420.00K1.49M[{"date":"2019-12-31","value":26.73,"profit":true},{"date":"2020-12-31","value":-630.57,"profit":false},{"date":"2021-12-31","value":0.2,"profit":true},{"date":"2022-12-31","value":28.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(20.60M)(19.31M)(20.17M)(18.84M)(14.12M)[{"date":"2019-12-31","value":-2059600000,"profit":false},{"date":"2020-12-31","value":-1930800000,"profit":false},{"date":"2021-12-31","value":-2017100000,"profit":false},{"date":"2022-12-31","value":-1883600000,"profit":false},{"date":"2023-12-31","value":-1412100000,"profit":false}]
Income Taxes(205.00K)9.21M2.33M(111.00K)1.31M[{"date":"2019-12-31","value":-2.23,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":25.35,"profit":true},{"date":"2022-12-31","value":-1.21,"profit":false},{"date":"2023-12-31","value":14.2,"profit":true}]
Income After Taxes(20.39M)(28.52M)(22.50M)(18.73M)(15.43M)[{"date":"2019-12-31","value":-2039100000,"profit":false},{"date":"2020-12-31","value":-2851500000,"profit":false},{"date":"2021-12-31","value":-2250500000,"profit":false},{"date":"2022-12-31","value":-1872500000,"profit":false},{"date":"2023-12-31","value":-1542810500,"profit":false}]
Income From Continuous Operations(20.60M)(19.31M)(20.17M)(18.84M)(16.25M)[{"date":"2019-12-31","value":-2059600000,"profit":false},{"date":"2020-12-31","value":-1930800000,"profit":false},{"date":"2021-12-31","value":-2017100000,"profit":false},{"date":"2022-12-31","value":-1883600000,"profit":false},{"date":"2023-12-31","value":-1625400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(20.39M)(28.52M)(22.50M)(18.73M)(14.12M)[{"date":"2019-12-31","value":-2039100000,"profit":false},{"date":"2020-12-31","value":-2851500000,"profit":false},{"date":"2021-12-31","value":-2250500000,"profit":false},{"date":"2022-12-31","value":-1872500000,"profit":false},{"date":"2023-12-31","value":-1412100000,"profit":false}]
EPS (Diluted)(27.60)(7.40)(8.63)(5.46)(3.86)[{"date":"2019-12-31","value":-2760,"profit":false},{"date":"2020-12-31","value":-740,"profit":false},{"date":"2021-12-31","value":-863,"profit":false},{"date":"2022-12-31","value":-546,"profit":false},{"date":"2023-12-31","value":-386,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PULM
Cash Ratio 18.27
Current Ratio 19.40
Quick Ratio 19.50

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PULM
ROA (LTM) -29.99%
ROE (LTM) -58.99%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PULM
Debt Ratio Lower is generally better. Negative is bad. 0.05
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.95

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PULM
Trailing PE NM
Forward PE NM
P/S (TTM) 1.93
P/B 2.01
Price/FCF NM
EV/R 1.12
EV/Ebitda 1.57
PEG NM

FAQs

What is Pulmatrix Inc share price today?

Pulmatrix Inc (PULM) share price today is $6.01

Can Indians buy Pulmatrix Inc shares?

Yes, Indians can buy shares of Pulmatrix Inc (PULM) on Vested. To buy Pulmatrix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PULM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Pulmatrix Inc be purchased?

Yes, you can purchase fractional shares of Pulmatrix Inc (PULM) via the Vested app. You can start investing in Pulmatrix Inc (PULM) with a minimum investment of $1.

How to invest in Pulmatrix Inc shares from India?

You can invest in shares of Pulmatrix Inc (PULM) via Vested in three simple steps:

  • Click on Sign Up or Invest in PULM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Pulmatrix Inc shares
What is Pulmatrix Inc 52-week high and low stock price?

The 52-week high price of Pulmatrix Inc (PULM) is $8.44. The 52-week low price of Pulmatrix Inc (PULM) is $1.55.

What is Pulmatrix Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Pulmatrix Inc (PULM) is

What is Pulmatrix Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Pulmatrix Inc (PULM) is 2.01

What is Pulmatrix Inc dividend yield?

The dividend yield of Pulmatrix Inc (PULM) is 0.00%

What is the Market Cap of Pulmatrix Inc?

The market capitalization of Pulmatrix Inc (PULM) is $21.95M

What is Pulmatrix Inc’s stock symbol?

The stock symbol (or ticker) of Pulmatrix Inc is PULM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top